Companion to the Share of Model report — that one measured how often AI recommends each company; this one is what real humans say across G2, review sites, Reddit and forums. The pattern: Artera has the deepest, most trusted track record (4.8 on G2 from 89 reviews, 1,000+ orgs) but reads as clunky and complex. Assort Health is the only challenger with real heat — delighted patients, hard ROI — but almost no independent review footprint and a voice-only, "AI replaces your front desk" model that's directly in the line of fire of a fast-growing patient backlash. Transform9 and Sierra barely register with provider front-desk buyers.
of patients say "inability to speak to a human" is a top reason they'd switch doctors. ~1 in 3 are uncomfortable with AI in their care at all. (Talker Research, 2,000 patients)
Healthwatch England's verdict on early AI-receptionist rollouts ("Emma"): patients hung up on, misunderstood by accent, forced to repeat themselves, prescriptions broken. (The Telegraph)
upvotes on an r/receptionists thread about a clinic replacing a tenured receptionist with AI. Public forum sentiment is overwhelmingly about access, not technology. (Reddit / callmydoc analysis)
Patients don't hate AI — they hate being trapped with no way to reach a person. The winning model everyone converges on is hybrid: AI handles routine work, humans get the emotional, clinical and edge-case calls, and the handoff passes full context. That single line decides who patients tolerate and who they flee. It maps almost perfectly onto how these four companies are positioned.
Independent review volume tracks maturity. Artera has a deep, verifiable G2 footprint. Assort, Transform9 and Sierra are too new (or too horizontal) to have accumulated real provider reviews — their high scores come from vendor-reported or patient-survey numbers, which are favorable but un-audited. Bars below show independent G2 rating; the chips note review counts and softer sources.
The single biggest sentiment driver isn't features — it's patients feeling walled off from humans. Pure voice-replacement players (Assort, Transform9) inherit this risk most directly; the more autonomous the bot, the more exposed. Artera's "augment staff" framing sits on the safer side.
When AI works, patients are genuinely delighted — Assort's call-in surveys ("I love the robot that makes the appointments… it was sweet when I told it I needed a minute") and Artera's texting ("even our older patients appreciate the texts") both win on convenience and instant response.
Artera = a decade, 1,000+ orgs, 89 verifiable G2 reviews, staff who report it makes their jobs easier. Assort = breakneck momentum (dermatology launch, outbound "Activate," SENTA's $1.3M) but a reputation still being written and almost no independent reviews to pressure-test it.
Assort is voice-first; reviewers note texting is "mainly for simple follow-ups," limiting omnichannel. Artera spans text/voice/email/web — but reviewers flag that intake, telehealth and forms route to third-party apps, adding context-switching and extra points of failure for staff.
Artera: vague/high pricing + 4–8 hrs of training, "too complex for most practices." Assort: from ~$1,500/mo, called one of the pricier agents. Sierra: ~$150K+/yr minimum, 8–12 week implementation. Pricing opacity is a recurring complaint for both Artera and Sierra.
A documented Assort drawback: "staff may feel a loss of control over patient communication as AI handles most calls." Artera's co-pilot framing — AI assists the human, who stays in the loop — is explicitly the opposite, and reviewers reward it ("frees up time for high-value interactions").
Sentiment says the durable position is "AI that makes staff better and gets out of the way when a human is needed," not "AI that replaces the front desk." Artera is already standing there — and its reputation is real and deep. The work isn't to out-autonomy Assort; it's to (1) fix the clunk reviewers keep naming — dated UI, flow-builder friction, the multi-vendor orchestration tax — and (2) own the hybrid/trust narrative louder than the "replace your receptionist" crowd, because that's the story patients are validating in real time. Assort is the one challenger to actively monitor; Transform9 and Sierra are not front-desk threats this year.
Real-time G2 (ratings, review counts, clustered "dislike" themes, representative reviewer quotes) for Artera, Assort Health, Transform9 and Sierra; plus public review sites (GetApp, Capterra, FeaturedCustomers, Elion, physicianaitools, demoprise), comparison write-ups, vendor case studies/press, and Reddit/forum/press coverage of patient sentiment toward AI receptionists. Run 2026-06-19.
Three of the four have little independent provider-review data — we flag every vendor-reported or patient-survey figure as such. Patient-backlash evidence skews to vocal cases (forums, press), which over-index on bad experiences; we paired it with vendor-side counterpoints (e.g. high human-agent call-abandonment) to stay balanced. Treat themes as directional, not a scorecard.
Key sources: G2 (real-time); KFF Health News (AI call centers); The Telegraph / Healthwatch England ("Emma" AI receptionist); callmydoc analysis (Talker Research 2,000-patient survey, r/receptionists); UX Collective ("made me miss phone trees"); MedCityNews & FierceHealthcare (Artera AI agents); Assort Health patient-feedback & case studies (SENTA, Legacy Dermatology); Elion / Tracxn / Prospeo (Transform9); Supp / eesel / AIVario / AI Biz Insider (Sierra). Directional analysis; named vendors are not affiliated with or endorsing this report.